Skip to main content
. 2022 Feb 21;2022:9557859. doi: 10.1155/2022/9557859

Figure 6.

Figure 6

The antitumor activity of si-TUG1-6 in vivo. (a) The image of tumor growth the introduction of each group. WNP: NCG mice injected with wide-type Hep3B cells, si-NC, and human PBMC; KNP; NCG mice injected with Hep3B-miRKO cells, si-NC, and human PBMC; KTP: NCG mice injected with Hep3B-miRKO cells, si-TUG1-6, and human PBMC. WTP: NCG mice injected with wide-type Hep3B cells, si-TUG1-6, and human PBMC. (b) Tumor volume and (c) tumor wright in each group. (d, e) Siglec-15 protein expression in tumors from each group. (f) RNA expression of Siglec-15, hsa-miR-582-5p, and TUG1 in tumors from each group. (g, h) Cytotoxicity of T cells from mice in each groups and cocultured with HUH7 and Hep3B cells. (i, j) IFN-γ and (k, l) IL-2 secreted by T cells from (g, h). The data are presented as the means ± SD, n = 6 samples and 3 replicates in (b–f), n = 3 replicates in (g–k). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005. S15: Siglec-15.